Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Nadia Gaudel-Dedieu"'
Autor:
Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel‐Dedieu, Bernard Sebastien, Hoai‐Thu Thai, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Helgi van de Velde, Christine Veyrat‐Follet, Dorothée Semiond
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 6, Pp 766-777 (2022)
Abstract Isatuximab is an approved anti‐CD38 monoclonal antibody with multiple antitumor modes of action. An exposure‐response (E‐R) analysis using data from patients with relapsed/refractory multiple myeloma (RRMM) enrolled in a phase Ib clini
Externí odkaz:
https://doaj.org/article/72a8ca4364ed43ceb08268319c1c852e
Autor:
Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel‐Dedieu, Bernard Sebastien, Hoai‐Thu Thai, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Helgi van de Velde, Christine Veyrat‐Follet, Dorothée Semiond
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 11:766-777
Isatuximab is an approved anti-CD38 monoclonal antibody with multiple antitumor modes of action. An exposure-response (E-R) analysis using data from patients with relapsed/refractory multiple myeloma (RRMM) enrolled in a phase Ib clinical study who r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9f2c0db9d6c587cf43463e77fd49629
https://doi.org/10.1002/psp4.12789
https://doi.org/10.1002/psp4.12789
Publikováno v:
Statistics in Medicine. 40:566-577
The Matching-Adjusted Indirect Comparison method (MAIC) is a recent methodology that allows to perform indirect comparisons between two drugs assessed in two different studies, where individual patients data are available in only one of the two studi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02c1265237b74056965f140f36296753
https://doi.org/10.1002/sim.8789
https://doi.org/10.1002/sim.8789
Autor:
Dorothée Semiond, Hoai-Thu Thai, Bernard Sebastien, Helgi van de Velde, Nadia Gaudel-Dedieu, Marc Cerou, Christine Veyrat-Follet
Publikováno v:
Cancer Research. 81:1372-1372
Introduction: Isa is a CD38 monoclonal antibody with multiple modes of action for killing tumor cells. Isa, in combination with pomalidomide and dexamethasone (Pd), is approved for the treatment of adult pts with RRMM who have received ≥2 prior the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e786453e39c4f3d647a375c9c6237c73
https://doi.org/10.1158/1538-7445.am2021-1372
https://doi.org/10.1158/1538-7445.am2021-1372
Autor:
Helgi van de Velde, Nadia Gaudel-Dedieu, Marc Cerou, Christine Veyrat-Follet, Dorothée Semiond, Hoai-Thu Thai, Bernard Sebastien
Publikováno v:
Blood. 136:44-44
Background: Isatuximab (Isa) is a CD38 monoclonal antibody with multiple modes of action for killing tumor cells through direct tumor targeting and immune cell engagement (Moreno, Clin Cancer Res, 2019). The addition of Isa to pomalidomide (P) and de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81b9237199b3d7e876a3016d7fb4d60b
https://doi.org/10.1182/blood-2020-139358
https://doi.org/10.1182/blood-2020-139358
Autor:
Helgi van de Velde, Frank Campana, Claire Brillac, Kimiko Koiwai, Jean Baptiste Fau, Fatiha Rachedi, Christine Veyrat-Follet, Dorothée Semiond, Hoai-Thu Thai, Raouf El-Cheikh, Nadia Gaudel-Dedieu, Li Liu, Bernard Sebastien, Laurent Nguyen
Publikováno v:
Blood. 134:1897-1897
Background: Isatuximab (Isa) is an anti-CD38 monoclonal antibody with multiple modes of action for killing tumor cells through direct tumor targeting and immune cell engagement. Exposure-Response (E-R) analysis and disease modelling of tumor burden w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::898280446b5a0ffc7c8a5b47b4021889
https://doi.org/10.1182/blood-2019-128875
https://doi.org/10.1182/blood-2019-128875